Drugs Made In America Acquisition Corp. (DMAA) Stock Price & Analysis
Drugs Made In America Acquisition Corp. (DMAA) rose 0.28% to USD 10.79 as of September 9, 2026 at 09:23 UTC, according to Nexqual real-time market data.
DMAA last closed at USD 10.76; the session ranged USD 10.76–10.79 on volume of 519,522 shares. Market capitalization is $261.95M, with a 52-week range of USD 10.23–10.79 (NGM). Source: Nexqual, September 9, 2026 at 09:23 UTC.
Key Statistics (as of September 9, 2026 at 09:23 UTC)
| Price | USD 10.79 |
|---|---|
| Change | ▲ 0.28% (up) |
| Previous Close | USD 10.76 |
| Open | USD 10.76 |
| Day Range | USD 10.76 – 10.79 |
| 52-Week Range | USD 10.23 – 10.79 |
| Volume | 519,522 shares |
| Market Cap | $261.95M |
| Exchange | NGM |
Technical Analysis (DMAA)
Nexqual's technical model rates DMAA "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of September 9, 2026 at 09:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 77.27 (overbought) |
| vs SMA50 | Above (USD 10.71) |
| MACD | 0.02 (positive) |
Analyst Ratings (DMAA)
Wall Street analysts rate DMAA "None", per Nexqual as of September 9, 2026 at 09:23 UTC.
| Consensus Rating | None |
|---|
Earnings (DMAA)
Source: Nexqual, September 9, 2026 at 09:23 UTC.
Financials & Fundamentals (DMAA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.02 |
| Total Cash | $20,280 |
| Total Debt | $350,000 |
Source: Nexqual, September 9, 2026 at 09:23 UTC.
Financial Health Score (DMAA)
Nexqual rates Drugs Made In America Acquisition Corp.'s overall financial health "Weak" across five dimensions, as of September 9, 2026 at 09:23 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $20K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$517K |
| Efficiency | Mixed — No data |
Ownership (DMAA)
| Insider Ownership | +23.57% |
|---|---|
| Institutional Ownership | +53.14% |
| Shares Outstanding | 24.28M |
| Float | 19.69M |
| Short % of Float | +0.41% |
Source: Nexqual, September 9, 2026 at 09:23 UTC.
Leadership (DMAA)
Drugs Made In America Acquisition Corp. is led by Roger Bendelac (age 68), Chief Executive Officer, per Nexqual as of September 9, 2026 at 09:23 UTC.
| Chief Executive Officer | Roger Bendelac (age 68) |
|---|---|
| CFO & Principal Accounting Officer | Saleem Elmasri (age 38) |
Major Backers & Investors (DMAA)
Notable institutional backers of Drugs Made In America Acquisition Corp. include Karpus Management, Inc., Mizuho Securities USA LLC, Polar Asset Management Partners Inc., according to Nexqual as of September 9, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Karpus Management, Inc. | 10.33% |
| Mizuho Securities USA LLC | 8.52% |
| Polar Asset Management Partners Inc. | 4.72% |
| Glazer Capital LLC | 4.12% |
| Wolverine Asset Management, LLC | 3.43% |
| Highbridge Capital Management, LLC. | 3.33% |
| First Trust Capital Management L.P. | 3.24% |
| INVESTMENT MANAGERS SERIES TRUST II-First Trust Merger Arbitrage Fund | 3.21% |
Source: Nexqual, September 9, 2026 at 09:23 UTC.
From Drugs Made In America Acquisition Corp.'s Latest SEC 10-K Filing (filed 2026-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- Because we are able to complete our initial business combination using our cash, debt or equity securities, or a combination of the foregoing, we have the flexibility to use the most efficient combination that will allow us to tailor the consideration to be paid to the target business to fit its needs and desires.
Partnerships
- Elmasri is expected to enter into an Indemnity Agreement, a Letter Agreement and a Registration Rights Agreement with the Company on the same terms as the other directors and officers of the Company that executed similar agreements at the time of the consummation of the Company's IPO.
- The Interim Loan represents a direct financial obligation of the Company.   On March 23, 2026, the Company entered into the Investment Agreement with the Investor relating to a proposed financing transaction pursuant to which the Investor indicated its intent to provide financing to the Company through a convertible note investment, of which the Interim Loan represented the first tranche.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DRDB | Roman DBDR Acquisition Corp. II | USD 10.68 | ▲ 0.09% |
| YHGJ | Yunhong Green CTI Ltd. | USD 2.75 | ▼ 1.41% |
| ATII | Archimedes Tech SPAC Partners I | USD 10.65 | ▲ 0.09% |
| BKHAU | Black Hawk Acquisition Corporat | USD 12 | ▼ 3.77% |
| AIFU | AIFU Inc. | USD 16.07 | ▼ 30.73% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 09:23 UTC. This page is informational and not investment advice.